Actively Recruiting

Phase 2
Age: 18Years - 70Years
All Genders
NCT07145229

Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare

Led by Atom Therapeutics Co., Ltd · Updated on 2025-12-08

380

Participants Needed

38

Research Sites

39 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

A randomized, double-blind, international multicenter, colchicine and placebo-controlled study to evaluate the efficacy and safety of ABP-745 in subjects with acute gout. Efficacy of ABP-745 in reducing pain and swelling compared with standard colchicine treatment and placebo will be evaluated in participants with acute gout. The primary efficacy measurement will be pain score after treatment.

CONDITIONS

Official Title

Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 to 70 years old, male or female
  • Body mass index (BMI) between 18 and 40 kg/m2
  • Medical history and current findings consistent with gouty arthritis diagnosis
  • Experienced 2 or more gout flares in the 12 months before screening
  • Onset of an acute gout flare within the last 6 months
  • Stable doses of urate-lowering therapy before and during the treatment period
  • Agreement to maintain a stable lifestyle including diet and exercise during the study period
Not Eligible

You will not qualify if you...

  • Use of oral prednisone 10 mg or higher, narcotics within 24 hours before first study drug dose, or glucocorticoid injection within 14 days before first dose
  • Use of nonsteroidal anti-inflammatory drugs before first study drug dose at investigator's discretion
  • Use of colchicine or ABP-745 within 14 days before first study drug dose
  • Participation in any clinical study with investigational drugs within 1 month before and during the study
  • Use of pegloticase, methotrexate, IL-1 blockers, TNF inhibitors, or other biologics within 30 days or 5 half-lives before first study drug dose
  • Use of muscle relaxants, central stimulants, barbiturates within 30 days or 5 half-lives before first study drug dose
  • Secondary gout caused by chemotherapy or transplant
  • Current or past rheumatoid arthritis, psoriatic arthritis, infectious/septic arthritis, CPP crystal arthritis, acute polyarticular gout (4 or more joints), multiple sclerosis, demyelinating diseases, major chronic inflammatory or connective tissue diseases other than RA or PsA
  • Prosthetic joint infection within 5 years or native joint infection within 1 year before screening
  • Current anticoagulation therapy, thrombocytopenia, or bleeding disorders
  • History of malignancy within 5 years except localized basal cell carcinoma
  • Significant diseases including uncontrolled hypertension, congestive heart failure NYHA class III or above, uncontrolled diabetes with HbA1c over 8.5%
  • Women of childbearing potential
  • Only no or mild gout-related pain before first study drug dose
  • Use of gout flare prophylaxis at randomization
  • COVID-19 vaccination within 4 weeks before randomization

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 38 locations

1

Onyx Clinical Research

Peoria, Arizona, United States, 61636

Actively Recruiting

2

Exinia Research

La Mesa, California, United States, 91942

Actively Recruiting

3

Evergreen Clinical Trial

Norcross, Georgia, United States, 30003

Not Yet Recruiting

4

Bioluminux Clinical Research

Naperville, Illinois, United States, 60540

Actively Recruiting

5

Exinia Research

Des Moines, Iowa, United States, 50308

Actively Recruiting

6

Northshore Research Associates

Alexandria, Louisiana, United States, 71303

Actively Recruiting

7

DelRicht Research

Baton Rouge, Louisiana, United States, 70769

Actively Recruiting

8

DelRicht Research

New Orleans, Louisiana, United States, 70115

Actively Recruiting

9

Interphase Clinical Trials

Lutherville, Maryland, United States, 21093

Actively Recruiting

10

DelRicht Research Gulfport

Gulfport, Mississippi, United States, 39501

Actively Recruiting

11

Albuquerque Clinical Trials, Inc.

Albuquerque, New Mexico, United States, 87176

Actively Recruiting

12

West Clinical Research

Morehead City, North Carolina, United States, 28557

Not Yet Recruiting

13

DelRicht Research

Tulsa, Oklahoma, United States, 74133

Actively Recruiting

14

Premier Family Physicians

Austin, Texas, United States, 78734

Not Yet Recruiting

15

Emeritus Sydney

Botany, New South Wales, Australia, 2019

Actively Recruiting

16

Canopy Clinical Research Northern Beaches

Brookvale, New South Wales, Australia, 2100

Actively Recruiting

17

Novatrials

Kotara, New South Wales, Australia, 2289

Actively Recruiting

18

Genesis Research Services

Newcastle, New South Wales, Australia, 2019

Actively Recruiting

19

Emeritus Melbourne

Camberwell, Victoria, Australia, 3124

Actively Recruiting

20

Canopy Clinical Research Altona North

North Altona, Victoria, Australia, 3025

Actively Recruiting

21

Peking University Third hospital

Beijing, Beijing Municipality, China, 100000

Actively Recruiting

22

Xuanwu Hospital Capital Medical University

Beijing, Beijing Municipality, China, 100000

Actively Recruiting

23

The second affiliated hospital of guangxi medical university

Nanning, Guangxi, China, 530000

Actively Recruiting

24

Hebei Petro China Central Hospital

Langfang, Hebei, China, 065000

Actively Recruiting

25

Wuhan UHospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China, 430000

Actively Recruiting

26

Xiangtan Central Hospital

Xiangtan, Hunan, China, 411100

Actively Recruiting

27

Xiangya Hospital Zhuzhou Central South University

Zhuzhou, Hunan, China, 412000

Actively Recruiting

28

Huai'an First People's Hospital

Huai'an, Jiangsu, China, 223000

Actively Recruiting

29

Pingxiang People's Hospital

Pingxiang, Jiangxi, China, 337000

Actively Recruiting

30

Zaozhuang Municipal Hospital

Zaozhuang, Shandong, China, 277100

Actively Recruiting

31

Huashan Hospital, Fudan University

Shanghai, Shanghai Municipality, China, 200040

Actively Recruiting

32

Linfen Central hospital

Linfen, Shanxi, China, 041000

Actively Recruiting

33

Shanxi Bethune Hospital

Taiyuan, Shanxi, China, 030000

Actively Recruiting

34

Shaanxi Provincial People's Hospital

Xi’an, Shanxi, China, 710000

Actively Recruiting

35

Xi'an Daxing Hospital

Xi’an, Shanxi, China, 710000

Actively Recruiting

36

Chengdu Fifth People's Hospital

Chengdu, Sichuan, China, 610000

Actively Recruiting

37

Hangzhou First People's Hospital

Hangzhou, Zhejiang, China, 310000

Actively Recruiting

38

Wenzhou People's Hospital

Wenzhou, Zhejiang, China, 325000

Actively Recruiting

Loading map...

Research Team

U

Ullrich Schwertschlag, MD,PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here